REFERENCES

Abderahmene, A., Ellouz, A., Amor, D., Ajmi, M., Khalij, Y., Hamdouni, H., Sahtout, W., Azzabi, A., Omezzine, A., Achour, A., & Bouslama, A. (2022). The pharmacogenetics of mycophenolate mofetil in Tunisian renal transplant patients. *Personalized Medicine*, *19*(5), 383–393. https://doi.org/10.2217/pme-2021-0092

Abecassis, M., Bartlett, S. T., Collins, A. J., Davis, C. L., Delmonico, F. L., Friedewald, J. J., Hays, R., Howard, A., Jones, E., Leichtman, A. B., Merion, R. M., Metzger, R. A., Pradel, F., Schweitzer, E. J., Velez, R. L., & Gaston, R. S. (2008). Kidney Transplantation as Primary Therapy for End-Stage Renal Disease. *Clinical Journal of the American Society of Nephrology*, *3*(2), 471–480. https://doi.org/10.2215/CJN.05021107

Alachkar, H., Mutonga, M., Kato, T., Kalluri, S., Kakuta, Y., Uemura, M., Imamura, R., Nonomura, N., Vujjini, V., Alasfar, S., Rabb, H., Nakamura, Y., & Alachkar, N. (2016). Quantitative Characterization of T-Cell Repertoire and Biomarkers in Kidney Transplant Rejection. *BMC Nephrology*, *17*(1), 181. https://doi.org/10.1186/s12882-016-0395-3

Alasfar, S., Kodali, L., & Schinstock, C. A. (2023). Current Therapies in Kidney Transplant Rejection. *Journal of Clinical Medicine*, *12*(15), 4927. https://doi.org/10.3390/jcm12154927

Alberts, B., Johnson, A., Lewis, J., Morgan, D., Raff, M., Roberts, K., & Walter, P. (2015). *Molecular Biology of The Cell* (Sixth edition). Garland Science.

Alelign, T., Ahmed, M. M., Bobosha, K., Tadesse, Y., Howe, R., & Petros, B. (2018). Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. *Journal of Immunology Research*, *2018*, 1–18. https://doi.org/10.1155/2018/5986740

Aneesh, T. P., M, S. S., Jose, A., Chandran, L., & Zachariah, S. M. (2009). Pharmacogenomics: The Right Drug to the Right Person. *Journal of Clinical Medicine Research*. https://doi.org/10.4021/jocmr2009.08.1255

Atcheson, B. A., Taylor, P. J., Mudge, D. W., Johnson, D. W., Hawley, C. M., Campbell, S. B., Isbel, N. M., Pillans, P. I., & Tett, S. E. (2005). Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. *British Journal of Clinical Pharmacology*, *59*(3), 271–280. https://doi.org/10.1111/j.1365-2125.2004.02235.x

Avasare, R., Drexler, Y., Caster, D. J., Mitrofanova, A., & Jefferson, J. A. (2023). Management of Lupus Nephritis: New Treatments and Updated Guidelines. *Kidney360*, *4*(10), 1503–1511. https://doi.org/10.34067/KID.0000000000000230

Balitbangkes. (2018). *Hasil Utama Riskesdas 2018*.

Balla, A., & Chobanian, M. (2009). New-onset diabetes after transplantation: a review of recent literature. *Current Opinion in Organ Transplantation*, *14*(4), 375–379. https://doi.org/10.1097/MOT.0b013e32832dbb98

Banasik, J. L., & Copstead, L.-E. C. (2019). *Pathophysiology* (6th edition). Elsevier.

Barnes, M. R., & Breen, G. (2010). *Genetic Variation: Methods and Protocols* (M. R. Barnes & G. Breen, Eds.; Vol. 628). Humana Press. https://doi.org/10.1007/978-1-60327-367-1

Barraclough, K. A., Lee, K. J., & Staatz, C. E. (2010a). Pharmacogenetic Influences on Mycophenolate Therapy. *Pharmacogenomics*, *11*(3), 369–390. https://doi.org/10.2217/pgs.10.9

Barraclough, K. A., Lee, K. J., & Staatz, C. E. (2010b). Pharmacogenetic influences on mycophenolate therapy. *Pharmacogenomics*, *11*(3), 369–390. https://doi.org/10.2217/pgs.10.9

Batalini, L. S., Castro, S. de O., G., C. G. R., Neitzke-Abreu, H. C., & L., M. S. da C. (2020). Evaluation of DNA Extraction Methods for Detection of Leishmania by Polymerase Chain Reaction. *American Journal of Molecular Biology*, *10*(04), 265–272. https://doi.org/10.4236/ajmb.2020.104018

Bergan, S., Brunet, M., Hesselink, D. A., Johnson-Davis, K. L., Kunicki, P. K., Lemaitre, F., Marquet, P., Molinaro, M., Noceti, O., Pattanaik, S., Pawinski, T., Seger, C., Shipkova, M., Swen, J. J., van Gelder, T., Venkataramanan, R., Wieland, E., Woillard, J.-B., Zwart, T. C., … Langman, L. J. (2021a). Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Therapeutic Drug Monitoring*, *43*(2), 150–200. https://doi.org/10.1097/FTD.0000000000000871

Bergan, S., Brunet, M., Hesselink, D. A., Johnson-Davis, K. L., Kunicki, P. K., Lemaitre, F., Marquet, P., Molinaro, M., Noceti, O., Pattanaik, S., Pawinski, T., Seger, C., Shipkova, M., Swen, J. J., van Gelder, T., Venkataramanan, R., Wieland, E., Woillard, J.-B., Zwart, T. C., … Langman, L. J. (2021b). Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. *Therapeutic Drug Monitoring*, *43*(2), 150–200. https://doi.org/10.1097/FTD.0000000000000871

Bertino, J. S., Kashuba, A. D. M., Ma, J. D., Fuhr, U., & DeVane, C. L. (2013). *Pharmacogenomics: An Introduction and Clinical Perspective*. McGraw-Hill.

Betonico, G. N., Abudd-Filho, M., Goloni-Bertollo, E. M., & Pavarino-Bertelli, E. (2008). Pharmacogenetics of mycophenolate mofetil: a promising different approach to tailoring immunosuppression? *Journal of Nephrology*, *21*(4), 503–509.

Bioneer. (2022). *Material Safety Data Sheet: GB Buffer*. https://eng.bioneer.com/literatures/msds/prep/MSDS_AccuPrep_Genomic_DNA_Extraction_Kit_GB_Buffer_EN_ver.2.pdf

Bouatou, Y., Viglietti, D., Pievani, D., Louis, K., Duong Van Huyen, J.-P., Rabant, M., Aubert, O., Taupin, J.-L., Glotz, D., Legendre, C., Loupy, A., & Lefaucheur, C. (2019). Response to Treatment and Long-Term Outcomes in Kidney Transplant Recipients with Acute T Cell–Mediated Rejection. *American Journal of Transplantation*, *19*(7), 1972–1988. https://doi.org/10.1111/ajt.15299

BPS. (2012). *Population of Indonesia: Result of Indonesia Population Census 2010*. Badan Pusat Statistik (Statistics Indonesia).

Brooker, R. J. (2018). *Genetics: Analysis & Principles* (Sixth edition). McGraw-Hill Education.

Brunton, L. S., & Knollmann, B. C. (2023). *Goodman and Gillman's The Pharmacological Basis Of Therapeutics* (Fourteenth Edition). McGraw Hill. https://ebooksmedicine.net/

Capriotti, T., & Frizzel, J. P. (2016). *Pathophysiology Introductory Concepts and Clinical Perspectives*. F.A. Davis Company. www.DavisAdvantage.com

Capriotti, T., & Frizzell, J. P. (2016). *Pathophysiology: Introductory Concepts and Clinical Perspectives*. F.A. Davis Company.

Chandran, S., & Mannon, R. B. (2022). T Cell–Mediated Rejection in Kidney Transplant Recipients: The end(point) is Also The Beginning. *American Journal of Transplantation*, *22*(3), 683–684. https://doi.org/10.1111/ajt.16964

Chariyavilaskul, P., Phaisal, W., Kittanamongkolchai, W., Rukrung, C., Anutrakulchai, S., & Avihingsanon, Y. (2022). Pharmacokinetics and Pharmacodynamics Profiles of Enteric-Coated Mycophenolate Sodium in Female Patients with Difficult-to-Treat Lupus Nephritis. *Clinical and Translational Science*, *15*(7), 1776–1786. https://doi.org/10.1111/cts.13295

Cheng, L., Yao, P., Weng, B., Yang, M., & Wang, Q. (2022). Meta-analysis of the associations of IMPDH and UGT1A9 polymorphisms with rejection in kidney transplant recipients taking mycophenolic acid. *European Journal of Clinical Pharmacology*, *78*(8), 1227–1238. https://doi.org/10.1007/s00228-022-03311-4

Cilião, H. L., Camargo-Godoy, R. B. O., Souza, M. F. de, Zanuto, A., Delfino, V. D. A., & Cólus, I. M. de S. (2018). Polymorphisms in IMPDH2, UGT2B7, and CES2 Genes Influence The Risk of Graft Rejection in Kidney Transplant Recipients Taking Mycophenolate Mofetil. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, *836*, 97–102. https://doi.org/10.1016/j.mrgentox.2018.06.008

Coffman, T. M., Falk, R. J., Molitoris, B. A., Neilson, E. G., & Schrier, R. W. (2013). *Schrier's Diseases of The Kidney Volume II* (9th ed). Wolters Kluwer Health/Lippincott Williams & Wilkins.

Corrêa, R. R. M., Machado, J. R., da Silva, M. V., Helmo, F. R., Guimarães, C. S. O., Rocha, L. P., Faleiros, A. C. G., & dos Reis, M. A. (2013). The Importance of C4d in Biopsies of Kidney Transplant Recipients. *Clinical and Developmental Immunology*, *2013*, 1–8. https://doi.org/10.1155/2013/678180

Dave, V., Polkinghorne, K. R., Leong, K. G., Kanellis, J., & Mulley, W. R. (2020). Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. *Scientific Reports*, *10*(1), 19379. https://doi.org/10.1038/s41598-020-76379-6

DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. (2017). *Pharmacotherapy A Pathophysiologic Approach* (10th Edition). McGraw-Hill.

Doi, Y., Kitayama, H., Yamada, M., & Miyama, Y. (2019). Severe Complications from an Unexpectedly High Serum Mycophenolic Acid Concentration in a Patient with Renal Failure Secondary to Lupus Nephritis: A Case Report. *Case Reports in Nephrology and Dialysis*, *9*(2), 72–78. https://doi.org/10.1159/000500516

Eide, I. A., Halden, T. A. S., Hartmann, A., Dahle, D. O., Åsberg, A., & Jenssen, T. (2017). Associations Between Posttransplantation Diabetes Mellitus and Renal Graft Survival. *Transplantation*, *101*(6), 1282–1289. https://doi.org/10.1097/TP.0000000000001259

Elston, R. C. (2017). *Statistical Human Genetics* (Vol. 1666). Springer New York. https://doi.org/10.1007/978-1-4939-7274-6

Etxebarria, A., Díez-Martín, E., Astigarraga, E., & Barreda-Gómez, G. (2022). Role of the Immune System in Renal Transplantation, Types of Response, Technical Approaches and Current Challenges. *Immuno*, *2*(4), 548–570. https://doi.org/10.3390/immuno2040035

Farida, L. S., Thaha, M., & Susanti, D. (2018). Characteristics of Patients with End-Stage Renal Disease at Dialysis Unit Dr. Soetomo General Hospital Surabaya. *Biomolecular and Health Science Journal*, *1*(2), 97. https://doi.org/10.20473/bhsj.v1i2.9400

Farjadian, S. (2012). The significance of HLA typing in transplantation. *Journal of Nephropathology*, *1*(3), 160–161. https://doi.org/10.5812/nephropathol.8112

Fatchiyah, Arumingtyas, E. L., Widyarti, S., & Rahayu, S. (2011). *Biologi Molekular: Prinsip Dasar Analisis*. Erlangga.

Feehally, J., Flöge, J., Tonelli, M., & Johnson, R. J. (2019). *Comprehensive Clinical Nephrology* (Sixth edition). Elsevier.

Francis Lam, Y. W., & Scott, S. A. (2019). *Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation*.

Gelder, T. van. (2005). Mycophenolate Mofetil: How to Further Improve Using an Already Successful Drug? *American Journal of Transplantation*, *5*(2), 199–200. https://doi.org/10.1111/j.1600-6143.2005.00793.x

Geneaid. (2017). *Genomic DNA Mini Kit (Blood/Cultured Cell)*. https://www.geneaid.com/data/files/1605601647444535985.pdf

Gensburger, O., Van Schaik, R. H. N., Picard, N., Le Meur, Y., Rousseau, A., Woillard, J.-B., Van Gelder, T., & Marquet, P. (2010a). Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. *Pharmacogenetics and Genomics*, *20*(9), 537–543. https://doi.org/10.1097/FPC.0b013e32833d8cf5

Gensburger, O., Van Schaik, R. H. N., Picard, N., Le Meur, Y., Rousseau, A., Woillard, J.-B., Van Gelder, T., & Marquet, P. (2010b). Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil. *Pharmacogenetics and Genomics*, *20*(9), 537–543. https://doi.org/10.1097/FPC.0b013e32833d8cf5

Genvigir, F. D. V., Cerda, A., Hirata, T. D. C., Hirata, M. H., & Hirata, R. D. C. (2020). Mycophenolic Acid Pharmacogenomics in Kidney Transplantation. *Journal of Translational Genetics and Genomics*. https://doi.org/10.20517/jtgg.2020.37

Ghatak, S., Muthukumaran, R. B., & Nachimuthu, S. K. (2013). A Simple Method of Genomic DNA Extraction from Human Samples for PCR-RFLP Analysis. *Journal of Biomolecular Techniques : JBT*, jbt.13-2404-001. https://doi.org/10.7171/jbt.13-2404-001

Gilbert, S. J., Weiner, D. E., Bomback, A. S., Perazella, M. A., & Tonelli, M. (2018). *National Kidney Foundation's Primer on Kidney Disease* (Seventh Edition). Elsevier.

Glander, P., Sommerer, C., Arns, W., Ariatabar, T., Kramer, S., Vogel, E.-M., Shipkova, M., Fischer, W., Zeier, M., & Budde, K. (2010). Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. *Clinical Journal of the American Society of Nephrology*, *5*(3), 503–511. https://doi.org/10.2215/CJN.06050809

Gramlick, M. E., Trevillian, P., Palazzi, K. L., & Heer, M. K. (2022). Time to Move on: HLA Matching Should Be Reconsidered in Modern Deceased Donor Kidney

Allocation. *Transplantation Direct*, *8*(3), e1295. https://doi.org/10.1097/TXD.0000000000001295

Griffiths, A. J. F., Wessler, S. R., Carroll, S. B., & Doebley, J. (2012). *Introduction to Genetic Analysis* (Tenth Edition). W.H Freeman and Company.

Grinyó, J., Vanrenterghem, Y., Nashan, B., Vincenti, F., Ekberg, H., Lindpaintner, K., Rashford, M., Nasmyth-Miller, C., Voulgari, A., Spleiss, O., Truman, M., & Essioux, L. (2008). Association of four DNA polymorphisms with acute rejection after kidney transplantation. *Transplant International*, *21*(9), 879–891. https://doi.org/10.1111/j.1432-2277.2008.00679.x

Grossman, S., & Porth, C. (2014). *Porth's Pathophysiology: Concepts of Altered Health States* (9th edition). Wolters Kluwer Health-Lippincott Williams & Wilkins.

Gusev, E., Solomatina, L., Zhuravleva, Y., & Sarapultsev, A. (2021). The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation. *International Journal of Molecular Sciences*, *22*(21), 11453. https://doi.org/10.3390/ijms222111453

Hardinger, K. L., Hebbar, S., Bloomer, T., & Murillo, D. (2008). Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil. *Clinical Transplantation*, *22*(5), 555–561. https://doi.org/10.1111/j.1399-0012.2008.00820.x

Helanterä, I., & Mengel, M. (2022). Revisiting Acute T cell–Mediated Rejection in Kidney Allografts. *American Journal of Transplantation*, *22*(3), 681–682. https://doi.org/10.1111/ajt.16923

Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O'Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016). Global prevalence of chronic kidney disease - A systematic review and meta-analysis. In *PLoS ONE* (Vol. 11, Issue 7). Public Library of Science. https://doi.org/10.1371/journal.pone.0158765

Hirunsatitpron, P., Hanprasertpong, N., Noppakun, K., Pruksakorn, D., Teekachunhatean, S., & Koonrungsesomboon, N. (2022). Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis. *British Journal of Clinical Pharmacology*, *88*(2), 476–489. https://doi.org/10.1111/bcp.14979

Hricik, D. E. (2015). Transplant Immunology and Immunosuppression: Core Curriculum 2015. *American Journal of Kidney Diseases*, *65*(6), 956–966. https://doi.org/10.1053/j.ajkd.2015.01.026

Huether, S. E., Mccance, K. L., & Brashers, V. L. (2020). *Understanding Pathophysiology* (7th ed.). Elsevier.

Indonesian Renal Registry. (2020). *13th Annual Report of Indonesian Renal Registry 2020*. https://www.indonesianrenalregistry.org/data/IRR%202020.pdf

International Society of Nephrology. (2023). *ISN-Global Kidney Health Atlas*. International Society of Nephrology.

Johnston, A., He, X., & Holt, D. W. (2006). Bioequivalence of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: A Meta-Analysis of Three Studies in Stable Renal Transplant Recipients. *Transplantation*, *82*(11), 1413–1418. https://doi.org/10.1097/01.tp.0000242137.68863.89

Kalman, L., Agúndez, J., Appell, M. L., Black, J., Bell, G., Boukouvala, S., Bruckner, C., Bruford, E., Caudle, K., Coulthard, S., Daly, A., Tredici, A. Del, den Dunnen, J., Drozda, K., Everts, R., Flockhart, D., Freimuth, R., Gaedigk, A., Hachad, H., … Zanger, U. (2016). Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. *Clinical Pharmacology & Therapeutics*, *99*(2), 172–185. https://doi.org/10.1002/cpt.280

Kanbay, M., Siriopol, D., Guldan, M., Ozbek, L., Topcu, A. U., Siriopol, I., & Tuttle, K. (2025). Prognostic impact of post-transplant diabetes mellitus in kidney allograft recipients: a meta-analysis. *Nephrology Dialysis Transplantation*, *40*(3), 554–576. https://doi.org/10.1093/ndt/gfae185

Karnell, J. L., Karnell, F. G., Stephens, G. L., Rajan, B., Morehouse, C., Li, Y., Swerdlow, B., Wilson, M., Goldbach-Mansky, R., Groves, C., Coyle, A. J., Herbst, R., & Ettinger, R. (2011). Mycophenolic Acid Differentially Impacts B Cell Function Depending on the Stage of Differentiation. *The Journal of Immunology*, *187*(7), 3603–3612. https://doi.org/10.4049/jimmunol.1003319

Karp, G. (2004). *Cell and Molecular Biology : Concept and Experiments*. Wiley.

Kato, S., Chmielewski, M., Honda, H., Pecoits-Filho, R., Matsuo, S., Yuzawa, Y., Tranaeus, A., Stenvinkel, P., & Lindholm, B. (2008). Aspects of Immune Dysfunction in End-stage Renal Disease. *Clinical Journal of the American Society of Nephrology*, *3*(5), 1526–1533. https://doi.org/10.2215/CJN.00950208

Katz-Greenberg, G., & Shah, S. (2022). Sex and Gender Differences in Kidney Transplantation. *Seminars in Nephrology*, *42*(2), 219–229. https://doi.org/10.1016/j.semnephrol.2022.04.011

Katzung, B. G. (2018). *Basic & clinical pharmacology* (14th ed.). McGraw-Hill Education.

Kemenkes RI. (2023). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Ginjal Kronik*. Kementerian Kesehatan Republik Indonesia.

Khan, M. A., Hanna, A., Sridhara, S., Chaudhari, H., Me, H. M., Attieh, R. M., & Abu Jawdeh, B. G. (2025). Maintenance Immunosuppression in Kidney Transplantation:

A Review of the Current Status and Future Directions. *Journal of Clinical Medicine*, *14*(6), 1821. https://doi.org/10.3390/jcm14061821

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. (2009). KDIGO Clinical Practice Guideline for The Care of Kidney Transplant Recipients. *American Journal of Transplantation*, *9*(Suppl 3), S1–S157.

Kimmel, P. L., & Rosenberg, M. E. (2020). *Chronic Renal Disease* (Second edition). Academic Press/Elsevier.

Knechtle, S. J., Marson, L. P., & Morris, P. J. (2020). *Kidney Transplantation: Principles and Practice* (Eighth edition). Elsevier.

Koshy, L., Anju, A. L., Harikrishnan, S., Kutty, V. R., Jissa, V. T., Kurikesu, I., Jayachandran, P., Jayakumaran Nair, A., Gangaprasad, A., Nair, G. M., & Sudhakaran, P. R. (2017). Evaluating genomic DNA extraction methods from human whole blood using endpoint and real-time PCR assays. *Molecular Biology Reports*, *44*(1), 97–108. https://doi.org/10.1007/s11033-016-4085-9

Kovac, J., Rolon, M. L., Naum, M., & Lampel, K. A. (2022). DNA-Based Assays. In *Encyclopedia of Dairy Sciences* (pp. 356–362). Elsevier. https://doi.org/10.1016/B978-0-12-818766-1.00157-4

Kwon, H., Kim, Y. H., Ko, Y., Lim, S. J., Jung, J. H., Baek, C. H., Kim, H., Park, S.-K., Shin, S., & Cho, Y.-P. (2021). Pure T-Cell Mediated Rejection Following Kidney Transplant According to Response to Treatment. *PLOS ONE*, *16*(9), e0256898. https://doi.org/10.1371/journal.pone.0256898

Lamba, V., Sangkuhl, K., Sanghavi, K., Fish, A., Altman, R. B., & Klein, T. E. (2014). PharmGKB Summary: Mycophenolic Acid Pathway. *Pharmacogenetics and Genomics*, *24*(1), 73–79. https://doi.org/10.1097/FPC.0000000000000010

Langman, L. J., & Dasgupta, A. (2012). *Pharmacogenomics in clinical therapeutics*. Wiley-Blackwell.

Lee, J. R., & Muthukumar, T. (2012). Immunologic Concepts in Kidney Transplantation. In *Current Concepts in Kidney Transplantation*. InTech. https://doi.org/10.5772/53798

Lertdumrongluk, P., Somparn, P., Kittanamongkolchai, W., Traitanon, O., Vadcharavivad, S., & Avihingsanon, Y. (2010). Pharmacokinetics of mycophenolic acid in severe lupus nephritis. *Kidney International*, *78*(4), 389–395. https://doi.org/10.1038/ki.2010.170

López-Oliva, M. O., Flores, J., Madero, R., Escuin, F., Santana, M. J., Bellón, T., Selgas, R., & Jiménez, C. (2017). Cytomegalovirus infection after kidney transplantation and long-term graft loss. *Nefrología (English Edition)*, *37*(5), 515–525. https://doi.org/10.1016/j.nefroe.2016.11.018

Lusco, M. A., Fogo, A. B., Najafian, B., & Alpers, C. E. (2016). AJKD Atlas of Renal Pathology: Acute T-Cell–Mediated Rejection. *American Journal of Kidney Diseases*, *67*(5), e29–e30. https://doi.org/10.1053/j.ajkd.2016.03.004

McCune, J. S., Storer, B., Thomas, S., McKiernan, J., Gupta, R., & Sandmaier, B. M. (2018). Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. *Biology of Blood and Marrow Transplantation*, *24*(9), 1802–1807. https://doi.org/10.1016/j.bbmt.2018.04.006

Melo, Z., Ruiz-Pacheco, J. A., Mendoza-Cerpa, C. A., & Echavarria, R. (2018). Immunopathology of Kidney Transplantation. In *Pathophysiology - Altered Physiological States*. InTech. https://doi.org/10.5772/intechopen.70596

Mok, C. C., Teng, Y. K. O., Saxena, R., & Tanaka, Y. (2023). Treatment of lupus nephritis: consensus, evidence and perspectives. *Nature Reviews Rheumatology*, *19*(4), 227–238. https://doi.org/10.1038/s41584-023-00925-5

Morisky, D. E., Green, L. W., & Levine, D. M. (1986). Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence. *Medical Care*, *24*(1), 67–74. https://doi.org/10.1097/00005650-198601000-00007

Muntean, A., & Lucan, M. (2013). Immunosuppression in Kidney Transplantation. *Clujul Medical (1957)*, *86*(3), 177–180.

National Center for Biotechnology Information. (2017). *Restriction Fragment Length Polymorphism (RFLP)*. https://www.ncbi.nlm.nih.gov/probe/docs/techrflp/

NCBI. (2024). *IMPDH2 inosine monophosphate dehydrogenase 2 [Homo sapiens (human)]*. https://www.ncbi.nlm.nih.gov/gene/3615

Ngamvichchukorn, T., Ruengorn, C., Noppakun, K., Thavorn, K., Hutton, B., Sood, M. M., Knoll, G. A., & Nochaiwong, S. (2022). Association Between Pretransplant Dialysis Modality and Kidney Transplant Outcomes. *JAMA Network Open*, *5*(10), e2237580. https://doi.org/10.1001/jamanetworkopen.2022.37580

Nolan, C. J., Damm, P., & Prentki, M. (2011). Type 2 diabetes across generations: from pathophysiology to prevention and management. *The Lancet*, *378*(9786), 169–181. https://doi.org/10.1016/S0140-6736(11)60614-4

O'Neill, A. G., Burrell, A. L., Zech, M., Elpeleg, O., Harel, T., Edvardson, S., Mor-Shaked, H., Rippert, A. L., Nomakuchi, T., Izumi, K., & Kollman, J. M. (2023). Neurodevelopmental disorder mutations in the purine biosynthetic enzyme IMPDH2 disrupt its allosteric regulation. *Journal of Biological Chemistry*, *299*(8), 105012. https://doi.org/10.1016/j.jbc.2023.105012

Ossman, R., Jamme, M., Moulin, B., Legendre, C., Morelon, E., Frimat, L., Hourmant, M., Durrbach, A., Malvezzi, P., Rostaing, L., Luc Taupin, J., Mesnard, L., & Rondeau, E. (2020). Immunosuppression and Graft Rejection in Living-related

HLA-identical Renal Transplantation: The RADOVFULL Study. *Transplantation*, *104*(6), 1256–1262. https://doi.org/10.1097/TP.0000000000002937

Padmanabhan, S. (2014). *Handbook of Pharmacogenomics and Stratified Medicine*. Academic Press.

Palanisamy, A. P., Schiltz, C. E., Pilch, N. A., Hunt, K. J., Nadig, S. N., Dowden, J. E., McGillicuddy, J. W., Baliga, P. K., Chavin, K. D., & Taber, D. J. (2015). Cardiovascular risk factors contribute to disparities in graft outcomes in African American renal transplant recipients: A retrospective analysis. *Blood Pressure*, *24*(1), 14–22. https://doi.org/10.3109/08037051.2014.934527

Pandey, J., Sigdel, M. R., Nepali, R., Kafle, M. P., Shrestha, M., & Shah, D. S. (2025). WCN25-4313 ASSOCIATION BETWEEN TACROLIMUS TROUGH LEVEL AND INCIDENCE OF NEW ONSET DIABETES MELLITUS AFTER KIDNEY TRANSPLANTATION. *Kidney International Reports*, *10*(2), S554. https://doi.org/10.1016/j.ekir.2024.11.992

Pazik, J., Ołdak, M., Podgórska, M., Lewandowski, Z., Sitarek, E., Płoski, R., Szmidt, J., Chmura, A., Durlik, M., & Malejczyk, J. (2011). Lymphocyte Counts in Kidney Allograft Recipients Are Associated With IMPDH2 3757T>C Gene Polymorphism. *Transplantation Proceedings*, *43*(8), 2943–2945. https://doi.org/10.1016/j.transproceed.2011.08.037

Penezić, L., Nađ-Škegro, S., Hadžavdić, A., Ganoci, L., Kaštelan, Ž., Trkulja, V., & Božina, N. (2024). Inosine monophosphate dehydrogenase type 2 polymorphism IMPDH2 3757T>C (rs11706052) and 12-month evolution of the graft function in renal transplant recipients on mycophenolate-based immunosuppression. *The Pharmacogenomics Journal*, *24*(3), 15. https://doi.org/10.1038/s41397-024-00335-0

Perhimpunan Nefrologi Indonesia. (2013). *Konsensus Transplantasi Ginjal Perhimpunan Nefrologi Indonesia (PERNEFRI) 2013*. Perhimpunan Nefrologi Indonesia (PERNEFRI).

PharmGKB. (2025). *rs11706052*. https://www.pharmgkb.org/variant/PA166156443/overview

Phillips, B. L., & Callaghan, C. (2023). The Immunology of Organ Transplantation. *Surgery (Oxford)*, *41*(9), 543–551. https://doi.org/10.1016/j.mpsur.2023.06.004

Philogene, M. C., & Brennan, D. C. (2023). *Kidney transplantation in adults: HLA matching and outcomes*. https://www.uptodate.com/contents/kidney-transplantation-in-adults-hla-matching-and-outcomes#H758262768

Pierce, B. A. (2020). *Genetics A Conceptual Approach* (Seventh Edition). Macmillan International Higher Education .

Popović, L., & Bulum, T. (2025). New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences. *Diagnostics*, *15*(3), 284. https://doi.org/10.3390/diagnostics15030284

Rajendiran, A. K., Jeyachandran, D., Gopalakrishnan, N., Arumugam, V., Thanigachalam, D., & Ramanathan, S. (2021). Cytomegalovirus Infection and Kidney Transplantation- A Retrospective Study of Risk Factors and Long-Term Clinical Outcome. *Indian Journal of Transplantation*, *15*(2), 125–130. https://doi.org/10.4103/ijot.ijot_116_20

Sawinski, D., & Poggio, E. D. (2021). Introduction to Kidney Transplantation: Long-Term Management Challenges. *Clinical Journal of the American Society of Nephrology*, *16*(8), 1262–1263. https://doi.org/10.2215/CJN.13440820

Shah, S., Harwood, S. M., Döhler, B., Opelz, G., & Yaqoob, M. M. (2012). Inosine Monophosphate Dehydrogenase Polymorphisms and Renal Allograft Outcome. *Transplantation*, *94*(5), 486–491. https://doi.org/10.1097/TP.0b013e31825b7654

Shahbazi, F., Ranjbaran, M., Karami-far, S., Soori, H., & Manesh, H. (2015). Graft survival rate of renal transplantation during a period of 10 years in Iran. *Journal of Research in Medical Sciences*, *20*(11), 1046. https://doi.org/10.4103/1735-1995.172814

Shaw, L. M., Korecka, M., Venkataramanan, R., Goldberg, L., Bloom, R., & Brayman, K. L. (2003). Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies. *American Journal of Transplantation*, *3*(5), 534–542. https://doi.org/10.1034/j.1600-6143.2003.00079.x

Shrestha, B. M. (2013). Immunology for Renal Transplantation: A Review. *Journal of Transplantation Technologies & Research*, *04*(01). https://doi.org/10.4172/2161-0991.1000130

Snustad, D. P., & Simmons, M. J. (2012). *Principles of Genetics* (6th ed). Wiley.

Sombogaard, F. (2010). *Pharmacodynamic Monitoring of Inosine Monophosphate Dehydrogenase Activity: A Basis for Optimized and Individualized Mycophenolate Mofetil Therapy*. Erasmus University Rotterdam.

Sombogaard, F., van Schaik, R. H. N., Mathot, R. A., Budde, K., van der Werf, M., Vulto, A. G., Weimar, W., Glander, P., Essioux, L., & van Gelder, T. (2009). Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism. *Pharmacogenetics and Genomics*, *19*(8), 626–634. https://doi.org/10.1097/FPC.0b013e32832f5f1b

Tambur, A. R., Kosmoliaptsis, V., Claas, F. H. J., Mannon, R. B., Nickerson, P., & Naesens, M. (2021). Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen–matching priorities to improve transplant

outcomes? An expert review and recommendations. *Kidney International*, *100*(5), 1012–1022. https://doi.org/10.1016/j.kint.2021.06.026

ThermoFisher. (2025). *Restriction Fragment Length Polymorphism (RFLP) Analysis*. https://www.thermofisher.com/id/en/home/life-science/sequencing/fragment-analysis/restriction-fragment-length-polymorphism-rflp-analysis.html

Thongprayoon, C., Hansrivijit, P., Leeaphorn, N., Acharya, P., Torres-Ortiz, A., Kaewput, W., Kovvuru, K., Kanduri, S., Bathini, T., & Cheungpasitporn, W. (2020). Recent Advances and Clinical Outcomes of Kidney Transplantation. *Journal of Clinical Medicine*, *9*(4), 1193. https://doi.org/10.3390/jcm9041193

United States Renal Data System. (2023). *2023 USRDS Annual Data Report: Epidemiology of Kidney Disease in The United States* .

Wallace, D. J., & Hahn, B. H. (2019). *Dubois' Lupus Erythematosus and Related Syndromes* (Ninth Edition). Elsevier.

Wang, J., Zeevi, A., Webber, S., Girnita, D. M., Addonizio, L., Selby, R., Hutchinson, I. V., & Burckart, G. J. (2007). A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. *Pharmacogenetics and Genomics*, *17*(4), 283–290. https://doi.org/10.1097/FPC.0b013e328012b8cf

Watson, J. D., Baker, T. A., Bell, S. P., Gann, A., Levine, M., & Losick, R. (2014). *Molecular Biology of The Gene* (Seventh edition). Pearson.

Winnicki, W., Fichtenbaum, A., Mitulovič, G., Herkner, H., Regele, F., Baier, M., Zelzer, S., Wagner, L., & Sengoelge, G. (2022). Individualization of Mycophenolic Acid Therapy through Pharmacogenetic, Pharmacokinetic and Pharmacodynamic Testing. *Biomedicines*, *10*(11), 2882. https://doi.org/10.3390/biomedicines10112882

Winnicki, W., Weigel, G., Sunder-Plassmann, G., Bajari, T., Winter, B., Herkner, H., & Sengoelge, G. (2010). An inosine 5′-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid. *The Pharmacogenomics Journal*, *10*(1), 70–76. https://doi.org/10.1038/tpj.2009.43

Woillard, J.-B., Picard, N., Thierry, A., Touchard, G., & Marquet, P. (2014). Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. *Pharmacogenetics and Genomics*, *24*(5), 256–262. https://doi.org/10.1097/FPC.0000000000000045

Wouk, N. (2021). End-Stage Renal Disease: Medical Management. *American Family Physician*, *104*(5). www.aafp.org/afp

Wu, T., Peng, Y., Pelleymounter, L., Moon, I., Eckloff, B., Wieben, E., Yee, V., & Weinshilboum, R. (2010). Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics. *British Journal of Pharmacology*, *161*(7), 1584–1598. https://doi.org/10.1111/j.1476-5381.2010.00987.x

Xu, H., Ma, H., Zha, L., Li, Q., Yang, G., Pan, H., Fei, X., Xu, X., Xing, C., & Zhang, L. (2020). IMPDH2 promotes cell proliferation and epithelial-mesenchymal transition of non-small cell lung cancer by activating the Wnt/β-catenin signaling pathway. *Oncology Letters*, *20*(5), 1–1. https://doi.org/10.3892/ol.2020.12082

Yamamoto, I., Kawabe, M., Hayashi, A., Kobayashi, A., Yamamoto, H., & Yokoo, T. (2023). Challenges Posed by the Banff Classification: Diagnosis and Treatment of Chronic Active T-Cell-Mediated Rejection. *Nephron*, *147*(Suppl. 1), 74–79. https://doi.org/10.1159/000530158

Yoo, K. D., Kim, C. T., Kim, M.-H., Noh, J., Kim, G., Kim, H., An, J. N., Park, J. Y., Cho, H., Kim, K. H., Kim, H., Ryu, D.-R., Kim, D. K., Lim, C. S., Kim, Y. S., & Lee, J. P. (2016). Superior Outcomes of Kidney Transplantation Compared with Dialysis. *Medicine*, *95*(33), e4352. https://doi.org/10.1097/MD.0000000000004352

Yu, A. S. L., Chertow, G. M., Luyckx, V. A., Marsden, P. A., Skorecki, K., Taal, M. W., & Wasser, W. G. (2020). *Brenner & Rector's The Kidney* (Eleventh Edition). Elsevier.

Zdanowicz, M. M. (2017). *Concepts in Pharmacogenomics: Fundamentals and Therapeutic Applications in Personalized Medicine*. ASHP Publications.

Zolezzi, M. (2005). Mycophenolate Sodium versus Mycophenolate Mofetil: A Review of Their Comparative Features. *Saudi Journal of Kidney Diseases and Transplantation*, *16*(2). https://journals.lww.com/sjkd/fulltext/2005/16020/mycophenolate_sodium_versus_mycophenolate_mofetil_.2.aspx